HBOC-201对四种临床生化分析平台的分析干扰
该研究评估了牛血红蛋白聚合物HBOC-201(Hemopure)对四种临床生化分析平台26种常用分析物的干扰。在104项检测中,22.1%出现超过总允许误差50%的负误差,25.0%出现正偏倚,42.3%偏倚可接受,10.6%分析失败。结论认为HBOC-201对实验室检测构成挑战,需参考平台和项目选择。
要点
- HBOC-201可导致生化分析显著偏倚,22.1%检测负误差>0.5tAE。
- 25.0%检测正偏倚>0.5tAE,42.3%在可接受范围,10.6%分析失败。
- 干扰程度因平台、波长、稀释和反应方法而异,需针对性评估。
核心结论
- HBOC-201治疗性输血或体外添加可对四种常见生化平台产生显著分析干扰,需实验室关注。
研究设计与样本
- 研究观察了26种常用分析物在4种分析平台上的误差,样本来自治疗性输血HBOC-201的患者血浆及供体血按10% v/v添加HBOC-201。
主要发现
- 104项检测中,23项(22.1%)负误差比>0.5tAE,26项(25.0%)正偏倚>0.5tAE,44项(42.3%)偏倚在-0.5tAE至0.5tAE之间可接受。
- 11项(10.6%)检测在HBOC-201存在时分析失败。
- 误差按平台、波长、稀释和反应方法进一步细分。
关键数值与推荐
- 负误差>50%总允许误差(>0.5tAE)定义为显著负误差比,共23/104。
- 正偏倚>0.5tAE共26/104,可接受偏倚范围为-0.5tAE至0.5tAE,共44/104。
- 分析失败共11/104。
临床怎么用
- 实验室人员可参考本研究评估患者样本,为特定分析物选择最佳分析平台,并预测四种平台之外的偏倚。
局限性
- 研究仅涉及四种分析平台和26种分析物,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are 13 million blood transfusions each year in the US. Limitations in the donor pool, storage capabilities, mass casualties, access in remote locations and reactivity of donors all limit the availability of transfusable blood products to patients. HBOC-201 (Hemopure®) is a second-generation glutaraldehyde-polymer of bovine hemoglobin, which can serve as an "oxygen bridge" to maintain oxygen carrying capacity while transfusion products are unavailable. Hemopure presents the advantages of extended shelf life, ambient storage, and limited reactive potential, but its extracellular location can also cause significant interference in modern laboratory analyzers similar to severe hemolysis. METHODS: Observed error in 26 commonly measured analytes was determined on 4 different analytical platforms in plasma from a patient therapeutically transfused Hemopure as well as donor blood spiked with Hemopure at a level equivalent to the therapeutic loading dose (10% v/v). RESULTS: Significant negative error ratios >50% of the total allowable error (>0.5tAE) were reported in 23/104 assays (22.1%), positive bias of >0.5tAE in 26/104 assays (25.0%), and acceptable bias between -0.5tAE and 0.5tAE error ratio was reported in 44/104 (42.3%). Analysis failed in the presence of Hemopure in 11/104 (10.6%). Observed error is further subdivided by platform, wavelength, dilution and reaction method. CONCLUSION: Administration of Hemopure (or other hemoglobin-based oxygen carriers) presents a challenge to laboratorians tasked with analyzing patient specimens. We provide laboratorians with a reference to evaluate patient samples, select optimal analytical platforms for specific analytes, and predict possible bias beyond the 4 analytical platforms included in this study.
引用
- Korte EA, Pozzi N, Wardrip N, et al. Analytical interference of HBOC-201 (Hemopure, a synthetic hemoglobin-based oxygen carrier) on four common clinical chemistry platforms. Clin Chim Acta. 2018. PMID: 29580857. doi:10.1016/j.cca.2018.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。